Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children

Y. Yoshida, T. Inoue, T. Nishikido, M. Kameda, I. Takamatu, S. Doi (Osaka, Japan)

Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Session: Anti-inflammatory therapy for childhood asthma
Session type: Electronic Poster Discussion
Number: 2705
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Yoshida, T. Inoue, T. Nishikido, M. Kameda, I. Takamatu, S. Doi (Osaka, Japan). Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children. Eur Respir J 2007; 30: Suppl. 51, 2705

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol
Source: Eur Respir J 2001; 18: Suppl. 33, 331s
Year: 2001

Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2002; 20: Suppl. 38, 306s
Year: 2002

Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Use of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol in optimising the management of allergic bronchopulmonary aspergillosis (ABPA)
Source: Eur Respir J 2003; 22: Suppl. 45, 237s
Year: 2003

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

Systemic activity of inhaled beclomethasone dipropionate HFA: a comparison of volume spacers
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Vascular remodelling and inhaled beclomethasone dipropionate in COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 598s
Year: 2007

HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

Safety of beclomethasone HFA (HFA BDP) pMDI compared with beclomethasone CFC pMDI (CFC BDP) over 12 weeks
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Comparison of the effects of beclomethasone HFA (BDP- HFA) pMDI with beclomethasone CFC (BDP-CFC) pMDI on 10-hour urinary cortisol in healthy subjects
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Effect of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) on small airways involvement in asthma: assessment using impulse oscillometry system (IOS)
Source: Eur Respir J 2007; 30: Suppl. 51, 352s
Year: 2007

Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 471s
Year: 2002

Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients
Source: Eur Respir J 2005; 26: Suppl. 49, 180s
Year: 2005